Compare HPQ & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HPQ | INSM |
|---|---|---|
| Founded | 1939 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.8B | 23.0B |
| IPO Year | 2002 | 2000 |
| Metric | HPQ | INSM |
|---|---|---|
| Price | $25.58 | $94.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 24 |
| Target Price | $21.42 | ★ $201.17 |
| AVG Volume (30 Days) | ★ 21.6M | 4.2M |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $55,295,000,000.00 | N/A |
| Revenue This Year | $3.10 | $182.31 |
| Revenue Next Year | $0.39 | $65.19 |
| P/E Ratio | $24.53 | ★ N/A |
| Revenue Growth | ★ 3.24 | N/A |
| 52 Week Low | $17.56 | $70.57 |
| 52 Week High | $29.65 | $212.75 |
| Indicator | HPQ | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 57.84 | 27.16 |
| Support Level | $18.30 | N/A |
| Resistance Level | $26.04 | $166.81 |
| Average True Range (ATR) | 1.46 | 4.32 |
| MACD | 0.17 | 0.21 |
| Stochastic Oscillator | 54.67 | 4.96 |
HP (formerly Hewlett-Packard) is a behemoth in the PC and printing markets. It has focused on these markets since it exited IT infrastructure in 2015 with the split from Hewlett Packard Enterprise. HP focuses on the commercial market, but maintains sales of consumer devices and printers. The firm has a broad and global customer base, with only one third of sales coming from the US. HP completely outsources manufacturing and relies heavily on channel partners for its sales and marketing.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.